4-(2-benzoylhydrazino)-tetrahydro-(4H)-pyran | 194543-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-benzoylhydrazino)-tetrahydro-(4H)-pyran
• 英文别名: N'-(tetrahydro-2H-pyran-4-yl)benzohydrazide；N'-(oxan-4-yl)benzohydrazide
• CAS: 194543-20-9
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.271
• InChiKey: KAJNLEWWLWJZRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• SULFONYLUREIDOPYRAZOLE DERIVATIVES
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0885890A1

  公开（公告）日：1998-12-23

  A sulfonylureidopyrazole derivative of formula (1) or (2) is disclosed. The derivative has an inhibitory activity on endothelin converting enzyme, and is useful for treating or preventing various cardiac failures, tracheal constrictions, nervous disorders, parasecretion, vascular disorders, various ulcers and the like.

  公开了一种化学式（1）或（2）的磺酰脲吡唑衍生物。该衍生物对内皮素转化酶具有抑制活性，可用于治疗或预防各种心脏衰竭、气管收缩、神经紊乱、副分泌、血管紊乱、各种溃疡等疾病。
• Pharmaceutical compositions and dosage forms
  申请人：IGNYTA, INC.

  公开号：US11253515B2

  公开（公告）日：2022-02-22

  Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.

  本文公开了包括N-[5-(3,5-二氟苄基)-1H-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氢-2H-吡喃-4-基氨基)苯甲酰胺的药物组合物和剂型，这些药物组合物和剂型可用于治疗癌症患者。本公开还提供了制备这些药物组合物和剂型的方法，以及利用本文提供的药物组合物和剂型治疗癌症患者的方法。
• COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS
  申请人：Ignyta, Inc.

  公开号：EP3107541A1

  公开（公告）日：2016-12-28
• COMBINATIONS FOR THE TREATMENT OF NEUROBLASTOMA
  申请人：Ignyta, Inc.

  公开号：EP3227276A1

  公开（公告）日：2017-10-11
• METHODS FOR TREATING NEUROBLASTOMA
  申请人：IGNYTA, INC.

  公开号：US20170007599A1

  公开（公告）日：2017-01-12

  Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.